Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders - Joplin Globe

Submitted by Anonymous (not verified) on Tue, 10/18/2022 - 10:02

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders Joplin Globe

Log in to post comments